Abstract:Ethnopharmacological relevance Zhi-zi-chi decoction (ZZCD), from "Treatise on Febrile Diseases", is a typical traditional Chinese medicine herb pair, which consists of Gardeniae Fructus (GF) and Semen Sojae Praeparatu (SSP). In clinical research, ZZCD was widely used to fight depression, remove annoyance. Many studies have reported that gut microbiota is critical target for the influence of depress through gut-brain axis, and our previously studies have found that ZZCD exhibiting antidepressant effect was through the gut-brain axis. However, the specific mechanism by which gut microbiota mediates the pharmacokinetics parameters of active compounds from ZZCD during the process of depression treatment has not yet been studied. Aim of the study To explore the differences in pharmacokinetics characters of bioactive iridoids from ZZCD and study the changes of gut microbiota at different stages of depression with the personalized medicine of ZZCD. Materials and methods A new strategy exploring the relationship among disease phenotypes (D), intestinal microbiota (I), enzymes (E) and traits of metabolism (T) named as "DIET" was established. Firstly, a fast, selective and sensitive ultra-performance liquid chromatography coupled with tandem mass spectrometer (UPLC-MS/MS) was established and validated to quality the main bioactive compounds from ZZCD and compare the pharmacokinetics and bioavailability of different iridoids prototypes and metabolites from ZZCD between normal and chronic unpredictable mild stress rats. Subsequently, the activity of corresponding metabolic enzymes of anti-depressive compounds, β-glucosidases and sulfotransferases, were analyzed by ρ-nitrophenyl-β -D-glucopyranoside and sulfotransferases ELISA kits, respectively. Finally, 16S rRNA gene sequencing was adopt to analyze intestinal bacteria composition for the treatment of depression by ZZCD. Results The antidepressant effect of ZZCD was promoted due to the increased exposures and reduced eliminations of anti-depressive compounds, especially geniposide and genipin 1-gentiobioside, under the depression state. With the ZZCD treatment, the depression was improved, but the exposures of anti-depressive compounds from ZZCD gradually decreased. Meanwhile, there were the corresponding decreased trends on the activity of β-glucosidases and sulfotransferases. With the consumption of ZZDC and the improvement of depression, the exposures of anti-depressive iridoid glycosides decreased and the activity of metabolism enzymes restored. Meanwhile, the dysbiosis of pathogenic bacteria ( Bacteroidota ) induced by depression was ameliorated and the probiotics ( Firmicutes ) at the phylum and genus level raised, the two phyla are closely related to the production of β-glucosidase and sulfotransferases. Conclusions It is the first proposed that ZZCD could personalized to treat depression at different stages targeting gut microbiota and gut microbiome could emerged as a potential diagnostic and therapeutic biomarker in depression.

Systems biology approaches to identify potential targets and inhibitors of the intestinal microbiota to treat depression

Deciphering the gut microbiota's (Coprococcus and Subdoligranulum) impact on depression: Network pharmacology and molecular dynamics simulation

Depression-associated gut microbes, metabolites and clinical trials

Progress in the Application of Intestinal Flora in the Treatment of Depression

Deciphering the Gut Microbiome's Influence on Depression: A Community-Level Constraint-Based Metabolic modelling Approach

Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Review of research progress on intestinal microbiota based on metabolism and inflammation for depression

Gut microbiota mediates the pharmacokinetics of Zhi-zi-chi decoction for the personalized treatment of depression

Prebiotics for depression: how does the gut microbiota play a role?

Depressive Disorder Prevention by DIET Crosslink: Diet, Intestinal Microbiota, Enzyme and Traits of Metabolism

Mood and Microbes: a Comprehensive Review of Intestinal Microbiota’s Impact on Depression

Core Antibiotic Resistance Genes Mediate Gut Microbiota to Intervene in the Treatment of Major Depressive Disorder

Gut microbiota: A new target for traditional Chinese medicine in the treatment of depression

The Role of Probiotics and Their Metabolites in the Treatment of Depression

The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect

Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications

Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis

Study on the Antidepressant Effect of Zhizichi Decoction by Regulating Metabolism and Intestinal Flora

Research progress on intestinal flora and depression

Plant-derived bioactive components regulate gut microbiota to prevent depression and depressive-related neurodegenerative diseases: Focus on neurotransmitters

Gut-to-brain axis provides novel therapeutic targets for depression